Abstract
Adoptive cell therapies involve infusing engineered immune cells into cancer patients to recognize and eliminate tumor cells.Adoptive cell therapy,as a form of living drug,has undergone explosive growth over the past decade.The recognition of tumor antigens by the T-cell receptor(TCR)is one of the natural mechanisms that the immune system used to eliminate tumor cells.TCR-T cell therapy,which involves introducing exogenous TCRs into patients'T cells,isa novel cell therapy strategy.TCR-T celltherapy can target the entire proteome of cancer cells.Engineering T cells with exogenous TCRs to help patients combat cancer has achieved success in clinical trials,particularly in treating solid tumors.In this review,we examine the progress of TCR-T cell therapy over the past five years.This includes the discovery of new tumor antigens,protein engineering techniques for TCR,reprogramming strategies for TCR-T cell therapy,clinical studies on TCR-T cell therapy,and the advancement of TCR-T cell therapy in China,We also propose several potential directions for the future development of TCR-T cell therapy.
基金项目
startup funding from the Center for Excellence in Molecular Cell Science at the Chinese Academy of Science()
国家自然科学基金(82350107)
上海市浦江人才计划(23PJ1414300)
国家科技期刊平台
NSTL
万方数据